MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide license to develop and

Combines Amgen's Proprietary Antibodies and Xencor's XmAb® Bispecific Antibody Platform to Develop New Therapeutic Candidates Includes Xencor's Preclinical CD38 Bispecific T Cell Engager for Multiple Myeloma Xencor to Receive $45 Million Upfront Payment and Up to $1.7 Billion in Clinical,

Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases Thousand Oaks, Calif. and Monrovia, Calif. – (Jan. 6, 2011) – Amgen (NASDAQ: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb®5871, an Fc- engineered

SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response,

Bassil Dahiyat Named One of the World’s Top Young Innovators by Technology Review, MIT’s Magazine of Innovation. Dahiyat To Be Honored September 24-25 at The Emerging Technologies Conference at MIT

Antibodies engineered with Xencor's proprietary Xtend&#8482 technology for increasing antibody half-life

Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement Monrovia, CA – February 13, 2007. Xencor, Inc., a protein and antibody therapeutics development company, today announced a collaboration with Boehringer Ingelheim to optimize therapeutic monoclonal

IRVING, Texas and MONROVIA, Calif. , Aug. 2, 2022 /PRNewswire/ --  Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor , Inc. (NASDAQ: XNCR), a clinical-stage

IRVING, Texas and MONROVIA, Calif. , Jan. 5, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and  Xencor , Inc.  (NASDAQ: XNCR), a clinical-stage

(BW Healthwire)–April 18, 2002—Xencor’s President and CEO, Dr. Bassil Dahiyat Chairs Panel at CALBIOsummit 2002